lenamilast (ITG-1052) / Intragrand Pharma, Transpire Bio - LARVOL DELTA

Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor (The Manila Times) - "Transpire Bio Inc...today announced that it has signed an exclusive license agreement with Suzhou Intragrand Pharma Co., Ltd for ITG-1052, an investigational PDE4 inhibitor. ITG-1052 represents the addition of a New Chemical Entity to the Transpire Bio pipeline of innovative inhaled therapeutics....Through this agreement, we aim to utilize our vast expertise in developing inhaled therapeutics to progress ITG-1052 as a best-in-class inhaled treatment for idiopathic pulmonary fibrosis and other indications....Under the agreement, Intragrand has granted Transpire Bio an exclusive license to develop, manufacture, and commercialize ITG-1052 in all territories except China. Terms of the agreement are not disclosed."

Licensing / partnership • Idiopathic Pulmonary Fibrosis